Technical White Paper for Clinical Methodologies
Generates a deep technical white paper or educational document for clinical methodologies, focusing on scientific validity and regulatory context.
---
name: Technical White Paper for Clinical Methodologies
version: 0.1.0
description: Generates a deep technical white paper or educational document for clinical methodologies, focusing on scientific validity and regulatory context.
metadata:
domain: technical
complexity: high
tags:
- technical-writing
- white-paper
- clinical-trials
- data-science
- regulatory
requires_context: true
variables:
- name: paper_title
description: The title of the white paper.
required: true
default: "De-Risking Clinical Development: The Methodology of In Silico Trials"
- name: context_description
description: Context about the purpose and audience of the paper.
required: true
default: |
We need to prove to our clients that our "In Silico" simulations are scientifically valid and not just a "black box." I am providing you with the core pillars of our offering.
- name: source_material
description: The core concepts or pillars to cover in the paper.
required: true
default: |
* **Concept 1 (SCA):** Constructing "synthetic" arms using historical clinical trial data and RWE.
* **Concept 2 (Simulation):** Agent-based modeling to simulate protocol feasibility (predicting dropouts, site burden).
* **Concept 3 (Digital Twins):** Virtual physiological models for biomarker efficacy prediction.
- name: specific_requirements
description: Specific requirements for the body of the white paper.
required: true
default: |
2. **Methodology Section - Synthetic Control Arms:**
* Explain the statistical techniques used to match real-world data to trial patients (e.g., Propensity Score Matching, exact matching).
* Discuss how we handle data heterogeneity and bias.
3. **Methodology Section - Agent-Based Modeling:**
* Describe how "Agents" (patients/sites) are programmed. What variables define an agent? (e.g., compliance probability, distance to clinic, symptom severity).
* Explain how the simulation runs "Monte Carlo" style iterations to predict failure points.
4. **Methodology Section - Mechanistic Digital Twins:**
* Explain the difference between statistical modeling and physiological/mechanistic modeling.
* Case Study Example: Create a hypothetical scenario where a Digital Twin identifies that a drug only works on patients with a specific renal profile.
model: gpt-4
modelParameters:
temperature: 0.4
messages:
- role: system
content: |
You are a dual expert in Clinical Data Science and Regulatory Affairs. Your tone should be academic, authoritative, detailed, and technically precise. Use LaTeX formatting for any necessary mathematical concepts.
- role: user
content: |
**Context:**
{{context_description}}
**Source Material:**
{{source_material}}
**Task:**
Write a **Technical White Paper** titled *"{{paper_title}}"*. The paper must cover:
1. **Introduction:** Define the core subject and the current regulatory appetite for them (reference FDA guidance or EMA opinion papers if applicable).
{{specific_requirements}}
**Conclusion:** A summary of how these technologies converge to ensure protocol integrity.
testData:
- input: |
paper_title: "De-Risking Clinical Development: The Methodology of In Silico Trials"
context_description: |
We need to prove to our clients that our "In Silico" simulations are scientifically valid and not just a "black box." I am providing you with the core pillars of our offering.
source_material: |
* **Concept 1 (SCA):** Constructing "synthetic" arms using historical clinical trial data and RWE.
* **Concept 2 (Simulation):** Agent-based modeling to simulate protocol feasibility (predicting dropouts, site burden).
* **Concept 3 (Digital Twins):** Virtual physiological models for biomarker efficacy prediction.
specific_requirements: |
2. **Methodology Section - Synthetic Control Arms:**
* Explain the statistical techniques used to match real-world data to trial patients (e.g., Propensity Score Matching, exact matching).
* Discuss how we handle data heterogeneity and bias.
3. **Methodology Section - Agent-Based Modeling:**
* Describe how "Agents" (patients/sites) are programmed. What variables define an agent? (e.g., compliance probability, distance to clinic, symptom severity).
* Explain how the simulation runs "Monte Carlo" style iterations to predict failure points.
4. **Methodology Section - Mechanistic Digital Twins:**
* Explain the difference between statistical modeling and physiological/mechanistic modeling.
* Case Study Example: Create a hypothetical scenario where a Digital Twin identifies that a drug only works on patients with a specific renal profile.
expected: |
Introduction
Methodology
Conclusion
evaluators:
- name: Output contains Introduction header
regex:
pattern: (?i)Introduction
- name: Output contains Methodology or Concept headers
regex:
pattern: (?i)(Methodology|Synthetic|Simulation|Digital\s+Twin)